

AstraZeneca Allemansfond

The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

Performance

26.07.2024

| YTD | 1 week | 1 mth. | 3 mån | 1 year | 5 years | 10 years |
|--------|--------|--------|-------|--------|---------|----------|
| 18.87% | 0.27% | 2.13% | 4.05% | 22.57% | 116.71% | 305.86% |


Average performance

| Average. perf. | 2 years | 3 years | 5 years | 10 years |
|--------------------|---------|---------|---------|----------|
| Fund ¹ | 18.24% | 14.51% | 16.55% | 14.91% |
| Index ² | 17.68% | 11.44% | - | - |

¹ Calculated on the fund's monthly closing price

² Benchmark index: SIX SRI Sweden Index GI (60%), AstraZeneca (40%). The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

Five years performance



Portfolio



Stocks 98.86%
Bonds and Cash 1.14%

As of: 30.06.2024

Sweden 50.96%
United Kingdom 45.54%
Switzerland 3.50%

As of: 30.06.2024

Portfolio manager comments — Q2 2024

Fund performance was positive in Q2 and the fund rose just over 6.5% in SEK. However, returns were weighed down by the holding in the installation company Bravida when an incident of over-billing by one of the company's businesses was reported and confirmed. We have a close dialogue with management regarding the company's measures to strengthen internal routines and processes, which will be followed up. The fund was also negatively affected by the holdings in Autoliv and Volvo, which have been weighed down by concerns about a weaker economy.

The holdings with the strongest contribution to returns included AstraZeneca, ABB and Sweco. During the quarter AstraZeneca held a capital market day with positive outlooks. Both ABB and Sweco posted strength when the companies reported stronger than expected results.

The fund increased the holding in Sandvik, which has an attractive exposure to the

Fund manager



Ulrika Orstadius

Experience in the fund industry 2011.
Portfolio Manager since
1 November 2022.

| | |
|--------------------|----------------------|
| Main category | Equity Fund |
| Risk | 4 |
| Rate | 4190.10 (26.07.2024) |
| Reporting Currency | SEK |
| Price/Trade | Daily |
| Total Rating™ | ★★★★★ |

| | |
|------------------------|-------|
| Minimum investment | 0 SEK |
| Monthly savings | 0 SEK |
| Traded on the Internet | No |
| Management Fee | 0.9% |
| Entry charge | 0% |
| Exit charge | 0% |

| | |
|-----------------------------|------------|
| Fund assets | 4,925 MSEK |
| Distribution per fund unit | - |
| Distribution date | - |
| Fund, date of launch | 01.04.1984 |
| Share class, date of launch | 01.04.1984 |

Largest holdings

| | |
|--|--------|
| AstraZeneca PLC | 45.02% |
| Volvo AB Class B | 5.55% |
| Hexagon AB Class B | 4.62% |
| Skandinaviska Enskilda Banken AB Class A | 4.31% |
| Assa Abloy AB Class B | 4.24% |
| Essity AB Class B | 3.52% |
| ABB Ltd | 3.46% |
| Sandvik AB | 3.14% |
| Beijer Ref AB Class B | 3.13% |
| Svenska Handelsbanken AB Class A | 2.40% |

mining industry and the green transition. We decreased the holdings in Indutrade and Atlas Copco due to relatively high valuations. In the upcoming reporting period we will continue to focus on investee companies that have sustainable business models and competitive offers with sustainable growth even in a weaker economy.

As of: 11.07.2024

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. [Summary of investors' rights](#).

The fund's fact sheet, risk level, fund rules and prospectus are available at www.handelsbanken.se/funds. Handelsbanken does not assume liability for any errors in the information.

www.handelsbanken.se/funds

Handelsbanken